Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2016

Liquid Biopsies and Minimally-Invasive Diagnostics 2016



Keynote Speakers


Clark Chen
Co-Director, University of California-San Diego


Dolores Di Vizio
Professor, Cedars Sinai Medical Center


Michael Heller
Professor, University of California San Diego


Raghu Kalluri
Professor & Chairman, Department of Cancer Biology; Olla S. Stribling Distinguished Chair for Cancer Research, MD Anderson Cancer Center


Walter Koch
Vice President, Roche Molecular Systems


Fred Kramer
Professor of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School Rutgers University


Minetta Liu
Associate Professor and Chair, Oncology Research, Mayo Clinic


Y. Peng Loh
Chief and Senior Investigator, Section on Cellular Neurobiology, Eunice Kennedy Shriver National Institute of Child health and Human Development, National Institutes of Health (NIH)


Chamindie Punyadeera
Associate Professor, Institute of Health and Biomedical Innovation, Queensland University of Technology


Dominique PV de Kleijn
Professor Experimental Vascular Surgery, University Medical Center Utrecht, The Netherlands


Lidong Qin
Professor, CPRIT Scholar, Houston Methodist Research Institute


Sehyun Shin
Professor & Director, Korea University


John Sninsky
Chief Scientific Officer, CareDx


Steve Soper
Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas


AmirAli Talasaz
Co-Founder, President & COO, Guardant Health


Hsian-Rong Tseng
Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles


Weian Zhao
Associate Professor, Department of Biomedical Engineering, University of California-Irvine

Overview

The 3rd Annual Liquid Biopsies and Minimally-Invasive Diagnostics 2016 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.

This Liquid Biopsies Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers.  There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.

The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for patient monitoring and precision/targeted medicine.

Authors of best abstracts would be offered with the opportunity to publish their full articles in “Special Issue on Liquid Biopsy” of Cancer Translational Medicine Journal.

Agenda Topics

  • Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
  • Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
  • Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNA and Circulating microRNA/Long Non-Coding RNA
  • Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
  • US vs. EU vs. Asia/Pacific Regulatory Landscape for Novel Minimally-Invasive Diagnostics

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Distinguished Faculty

Muller Fabbri, Assistant Professor, University of Southern California
Shivani Sharma, Associate Director, California NanoSystems Institute, California NanoSystems Institute, UCLA
Louise Laurent, Associate Professor, University of California-San Diego
Kendall Van Keuren-Jensen, Associate Professor, Translational Genomics Research Institute
James Joyce, Chairman & CEO, Aethlon Medical, Inc.
Eric Kaldjian, Chief Medical Officer, RareCyte
Lyle Arnold, Chief Scientific Officer, Biocept
David Freedman, Co-Founder & CEO, nanoView Diagnostics Inc.
James Han, Director, Bioinformatics, Genomic Health
Ian Papautsky, Professor, Department of Bioengineering, University of Illinois at Chicago
Iwijn De Vlaminck, Robert N. Noyce Assistant Professor in Life Science and Technology Meinig School of Biomedical Engineering, Cornell University
Anders Nygren, Senior Director, Research and Development, Agena Biosciences
Lingzhi Wang, Senior Research Scientist, Ctr. for Translational Medicine, Adjunct Professor, National University of Singapore
Karl Hecker, Vice President of Product Development, Rubicon Genomics, Inc.


Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks